MC0704: Targeting STAT3 in Triple-negative Breast Cancer Research

Breast cancer (BC) remains a leading cause of cancer-related deaths in women, with some forms displaying high recurrence rates and metastatic potential. BC is typically classified by the presence of key receptors, including the human epidermal growth factor receptor, estrogen receptor, and progesterone receptor. These receptors are critical targets for therapy. However, approximately 20% of BC cases lack these receptors, a subtype known as triple-negative breast cancer (TNBC). TNBC is more aggressive, with fewer treatment options, leading to a poorer prognosis compared to other BC types. Metastatic TNBC (mTNBC) is particularly difficult to treat, and STAT3 has emerged as a promising therapeutic target in this context.

MC0704 is a novel STAT3 inhibitor that has shown significant potential in the treatment of TNBC. It has an IC50 value of 2.13 μM and is effective against both paclitaxel- and docetaxel-resistant TNBC cells in vitro and in vivo.

In various studies, MC0704 demonstrated its ability to induce cell cycle arrest, promote apoptosis, and inhibit tumour growth in animal models. Moreover, when combined with docetaxel, MC0704 enhances the anti-tumour effect, offering a promising approach for TNBC treatment.

For a detailed look into the research behind MC0704 and its potential as a therapeutic agent, visit MedChemExpress LLC to read the full article:

MC0704: A STAT3 Inhibitor for Triple-negative Breast Cancer Research.